{
  "page_id": 1,
  "metadata": {
    "file_name": "doc_0994.png",
    "image_width": 754,
    "image_height": 1000
  },
  "lines": [
    {
      "text": "Addietive Behaviors. Vol. 22. No. 6. pp. 753-757. 1997",
      "bbox": [
        407,
        157,
        661,
        177
      ],
      "confidence": 0.9306222200393677
    },
    {
      "text": "Pergamon",
      "bbox": [
        156,
        171,
        221,
        189
      ],
      "confidence": 0.9988831877708435
    },
    {
      "text": "Copyright © 1997 Elsevier Seience Ltd",
      "bbox": [
        476,
        169,
        661,
        188
      ],
      "confidence": 0.9056916236877441
    },
    {
      "text": "Printed in the USA. Alf rights reservied",
      "bbox": [
        475,
        179,
        661,
        200
      ],
      "confidence": 0.9616401791572571
    },
    {
      "text": "PIT S0306-4603(97)00041-5",
      "bbox": [
        294,
        198,
        457,
        221
      ],
      "confidence": 0.9788709878921509
    },
    {
      "text": "0306-4603/97$17.00 +.00",
      "bbox": [
        531,
        191,
        661,
        210
      ],
      "confidence": 0.9853015542030334
    },
    {
      "text": "A COMPARISON OF MEASURES USED TO ASSESS",
      "bbox": [
        158,
        248,
        587,
        280
      ],
      "confidence": 0.987740159034729
    },
    {
      "text": "EFFECTIVENESS OF THE TRANSDERMAL NICOTINE PATCH",
      "bbox": [
        108,
        267,
        638,
        300
      ],
      "confidence": 0.9951735138893127
    },
    {
      "text": "ATIYEAR",
      "bbox": [
        326,
        290,
        422,
        311
      ],
      "confidence": 0.9422152638435364
    },
    {
      "text": "ROBYNL. RICHMOND",
      "bbox": [
        285,
        317,
        462,
        339
      ],
      "confidence": 0.9635925889015198
    },
    {
      "text": "School of Communjty Medicine, University of New South Wales",
      "bbox": [
        197,
        333,
        546,
        357
      ],
      "confidence": 0.9761889576911926
    },
    {
      "text": "12-month outcomes of the nicotine transdermal palch using different measures of effective-",
      "bbox": [
        117,
        367,
        625,
        394
      ],
      "confidence": 0.9817191362380981
    },
    {
      "text": "Abstract  This study cxamines outcome measures of abstinence among studies reporting",
      "bbox": [
        118,
        354,
        626,
        383
      ],
      "confidence": 0.9797065258026123
    },
    {
      "text": "ness. This was achieved by reviewing published randomized controlted studies reporting",
      "bbox": [
        116,
        379,
        626,
        406
      ],
      "confidence": 0.9805259704589844
    },
    {
      "text": "I-year abstinence ratcs of the nicotine transdermal patch, Comparisons are made ncrcss stud-",
      "bbox": [
        117,
        391,
        625,
        417
      ],
      "confidence": 0.9707953333854675
    },
    {
      "text": "prolonged abstinence. Studies that measured outcome in terms of continuous and prolonged",
      "bbox": [
        115,
        412,
        627,
        443
      ],
      "confidence": 0.9511502981185913
    },
    {
      "text": "ies of three outcome measures use.t to report abstinence: point prevalence, continuous, and",
      "bbox": [
        116,
        402,
        625,
        429
      ],
      "confidence": 0.9323316216468811
    },
    {
      "text": "outcome measure.  1997 Elsevier Science Ltd",
      "bbox": [
        115,
        450,
        399,
        469
      ],
      "confidence": 0.9299734234809875
    },
    {
      "text": "Nicotince transdermal patches were developcd as an aid to smoking cessation and arc",
      "bbox": [
        75,
        487,
        664,
        518
      ],
      "confidence": 0.9697629809379578
    },
    {
      "text": "designed to offer an efficient method of delivering nicotine in a controlled and contin-",
      "bbox": [
        76,
        503,
        664,
        532
      ],
      "confidence": 0.9835003018379211
    },
    {
      "text": "uous way (Palmer. Buckley, & Faulds, 1992) so that withdrawal symptoins are allevi-",
      "bbox": [
        77,
        519,
        663,
        547
      ],
      "confidence": 0.9534952640533447
    },
    {
      "text": "ated. Compared to other nicotine replacement therapies (gum and nasal spray). trans-",
      "bbox": [
        77,
        535,
        663,
        562
      ],
      "confidence": 0.9848195910453796
    },
    {
      "text": "dermal patches appear to offer the best risk-to-benefit ratio: they combinc good",
      "bbox": [
        77,
        550,
        663,
        577
      ],
      "confidence": 0.9809466600418091
    },
    {
      "text": "smoking cessation efficacy and withdrawal supprcssion with a modest adverse effect",
      "bbox": [
        77,
        566,
        662,
        592
      ],
      "confidence": 0.98525071144104
    },
    {
      "text": "profile and low abuse liability (Gross & Stitzer, 19s9). Further, there is a high compli-",
      "bbox": [
        77,
        582,
        660,
        607
      ],
      "confidence": 0.9773898124694824
    },
    {
      "text": "ance and paticnt acceptance. of the patches compared to the gum (Mendelsohn &",
      "bbox": [
        77,
        599,
        659,
        622
      ],
      "confidence": 0.9654956459999084
    },
    {
      "text": "Richmond,1994).",
      "bbox": [
        76,
        613,
        200,
        634
      ],
      "confidence": 0.9951547980308533
    },
    {
      "text": "Criteria for reporting abstinence in smoking cessation trials use one of thrce alter-",
      "bbox": [
        90,
        629,
        656,
        654
      ],
      "confidence": 0.9880328178405762
    },
    {
      "text": "native outcome measures to cvaluate efficacy. Thcy are (a) point prevalence, the per-",
      "bbox": [
        76,
        645,
        658,
        668
      ],
      "confidence": 0.9794780015945435
    },
    {
      "text": "centage of people not smoking at a particular point in time, including long-term and",
      "bbox": [
        76,
        659,
        658,
        683
      ],
      "confidence": 0.9840741753578186
    },
    {
      "text": "short-term quitters; (b) continuous abstinence, the most conseryative mcasure of out-",
      "bbox": [
        76,
        675,
        654,
        696
      ],
      "confidence": 0.9721851348876953
    },
    {
      "text": "come, which is the percentage of people who have not smokcd at all since commence-",
      "bbox": [
        77,
        689,
        652,
        710
      ],
      "confidence": 0.9919805526733398
    },
    {
      "text": "ment of thc intervention to the 12-month follow-up point: and (c) prolongcd absti-",
      "bbox": [
        77,
        705,
        652,
        724
      ],
      "confidence": 0.9630501866340637
    },
    {
      "text": "nence. the percentage who have been continuously abstinent for a prolonged period",
      "bbox": [
        77,
        719,
        651,
        738
      ],
      "confidence": 0.9761797189712524
    },
    {
      "text": "since thc previous assessment (Velicer, Prochaska, Rossi, & Snow. 1992). The out-",
      "bbox": [
        75,
        733,
        650,
        754
      ],
      "confidence": 0.9601702094078064
    },
    {
      "text": "come measure of prolongcd abstinence reflects the natural process of stopping smok-",
      "bbox": [
        78,
        750,
        648,
        767
      ],
      "confidence": 0.9962656497955322
    },
    {
      "text": "ing, as some smokers succeed in quitting only after experiencing a scrics of delayed quit",
      "bbox": [
        77,
        764,
        648,
        783
      ],
      "confidence": 0.9846639037132263
    },
    {
      "text": "attempts, lapses, and relapses following an intervention (Prochaska & DiClcmcntc.",
      "bbox": [
        77,
        778,
        647,
        799
      ],
      "confidence": 0.9823167324066162
    },
    {
      "text": "1986). Although continuous abstinence may not account for this frequent occurrence",
      "bbox": [
        77,
        792,
        646,
        815
      ],
      "confidence": 0.9848614931106567
    },
    {
      "text": "in the dynamic process of quitting, it is regarded as the most rigorous measure, as ab-",
      "bbox": [
        77,
        808,
        643,
        830
      ],
      "confidence": 0.9817318916320801
    },
    {
      "text": "stinence is considered to be a dircct result of intervention. Thcrcfore., the gold stan-",
      "bbox": [
        76,
        821,
        643,
        846
      ],
      "confidence": 0.9702489972114563
    },
    {
      "text": "dards for presenting efficacy are 12-month validated continuous or prolonged smoking",
      "bbox": [
        77,
        836,
        642,
        861
      ],
      "confidence": 0.981983482837677
    },
    {
      "text": "abstinence ratcs, as thcse measures demonstrate stable abstinence over time.",
      "bbox": [
        77,
        851,
        584,
        876
      ],
      "confidence": 0.9666842222213745
    },
    {
      "text": "A meta-analysis of 17 clinical trials of the nicotine transdermal patch using absti-",
      "bbox": [
        94,
        866,
        636,
        889
      ],
      "confidence": 0.9817425608634949
    },
    {
      "text": "nence at 6 months found 22% for active treatment and 9% for placebo (odds ratio was",
      "bbox": [
        78,
        881,
        638,
        903
      ],
      "confidence": 0.9847813844680786
    },
    {
      "text": "Requests for reprints should be sent 1o Robyn L. Richinond. School of Comimunity Medicine. University",
      "bbox": [
        90,
        904,
        637,
        932
      ],
      "confidence": 0.940803050994873
    },
    {
      "text": "753",
      "bbox": [
        350,
        945,
        371,
        959
      ],
      "confidence": 0.9946563839912415
    }
  ],
  "full_text": "Addietive Behaviors. Vol. 22. No. 6. pp. 753-757. 1997\nPergamon\nCopyright © 1997 Elsevier Seience Ltd\nPrinted in the USA. Alf rights reservied\nPIT S0306-4603(97)00041-5\n0306-4603/97$17.00 +.00\nA COMPARISON OF MEASURES USED TO ASSESS\nEFFECTIVENESS OF THE TRANSDERMAL NICOTINE PATCH\nATIYEAR\nROBYNL. RICHMOND\nSchool of Communjty Medicine, University of New South Wales\n12-month outcomes of the nicotine transdermal palch using different measures of effective-\nAbstract  This study cxamines outcome measures of abstinence among studies reporting\nness. This was achieved by reviewing published randomized controlted studies reporting\nI-year abstinence ratcs of the nicotine transdermal patch, Comparisons are made ncrcss stud-\nprolonged abstinence. Studies that measured outcome in terms of continuous and prolonged\nies of three outcome measures use.t to report abstinence: point prevalence, continuous, and\noutcome measure.  1997 Elsevier Science Ltd\nNicotince transdermal patches were developcd as an aid to smoking cessation and arc\ndesigned to offer an efficient method of delivering nicotine in a controlled and contin-\nuous way (Palmer. Buckley, & Faulds, 1992) so that withdrawal symptoins are allevi-\nated. Compared to other nicotine replacement therapies (gum and nasal spray). trans-\ndermal patches appear to offer the best risk-to-benefit ratio: they combinc good\nsmoking cessation efficacy and withdrawal supprcssion with a modest adverse effect\nprofile and low abuse liability (Gross & Stitzer, 19s9). Further, there is a high compli-\nance and paticnt acceptance. of the patches compared to the gum (Mendelsohn &\nRichmond,1994).\nCriteria for reporting abstinence in smoking cessation trials use one of thrce alter-\nnative outcome measures to cvaluate efficacy. Thcy are (a) point prevalence, the per-\ncentage of people not smoking at a particular point in time, including long-term and\nshort-term quitters; (b) continuous abstinence, the most conseryative mcasure of out-\ncome, which is the percentage of people who have not smokcd at all since commence-\nment of thc intervention to the 12-month follow-up point: and (c) prolongcd absti-\nnence. the percentage who have been continuously abstinent for a prolonged period\nsince thc previous assessment (Velicer, Prochaska, Rossi, & Snow. 1992). The out-\ncome measure of prolongcd abstinence reflects the natural process of stopping smok-\ning, as some smokers succeed in quitting only after experiencing a scrics of delayed quit\nattempts, lapses, and relapses following an intervention (Prochaska & DiClcmcntc.\n1986). Although continuous abstinence may not account for this frequent occurrence\nin the dynamic process of quitting, it is regarded as the most rigorous measure, as ab-\nstinence is considered to be a dircct result of intervention. Thcrcfore., the gold stan-\ndards for presenting efficacy are 12-month validated continuous or prolonged smoking\nabstinence ratcs, as thcse measures demonstrate stable abstinence over time.\nA meta-analysis of 17 clinical trials of the nicotine transdermal patch using absti-\nnence at 6 months found 22% for active treatment and 9% for placebo (odds ratio was\nRequests for reprints should be sent 1o Robyn L. Richinond. School of Comimunity Medicine. University\n753"
}